Acutaas Chemicals logo

Acutaas Chemicals

ACUTAAS NSE

Key Fundamentals

SmallcapPharmaceuticalsHealthcare
Market Cap
₹26,347 Cr
Volatility
Moderate
P/E Ratio
67.77
EBITDA
₹522 Cr
Return on Equity
20.83%
Debt to Equity
0.02
Book Value
₹201.97
EPS
₹15.13
52W High
₹3,740
52W Low
₹1,302

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 45.8% CAGR over last 5 years

Weaknesses

2
  • Stock is trading at 15.8 times its book value
  • Promoter holding has decreased over last 3 years: -6.27%

Growth Rate

Revenue Growth
34.89% higher than 3Y
Net Income Growth
122% higher than 3Y
Cash Flow Change
147% higher than 3Y
ROE
71.44% higher than 3Y
ROCE
67.9% lower than 3Y
EBITDA Margin (Avg.)
55.43% lower than 3Y

AI Analysis — Bull vs Bear

6d ago
AI opinion · based on fundamentals
Risk high

Acutaas Chemicals Ltd (formerly Ami Organics) has a market capitalisation of about ₹26,595 crore. Its TTM sales grew 41% and TTM profit grew 104%, with 5-year compounded sales and profit growth of 32% and 46%. The stock trades at 69.5x earnings and 16.28x book value after a 141% gain over the past year. The company is almost debt free, and promoter holding has fallen by 6.75 percentage points over three years.

Bull Case 7
  • Profit growth has sped up. TTM profit growth of 104% is well above the 3-year CAGR of 62% and the 5-year CAGR of 46%.
  • Sales growth is steady over time. Compounded sales growth was 30% over 3 years, 32% over 5 years and 41% on a TTM basis, so the gains are not a one-off.
  • Return on equity rose to 24% last year from a 3-year average of 18%, which suggests capital is being used more efficiently as the business grows.
  • Profit is growing faster than sales. TTM profit growth of 104% versus TTM sales growth of 41% points to operating leverage and margin expansion.
  • The company is almost debt free, which leaves room to fund growth without adding leverage risk. Its implied TTM net profit is about ₹383 crore (₹26,595 crore market cap ÷ 69.5 P/E).
  • Returns have compounded over several periods: 74% CAGR over 3 years and 39% CAGR over 5 years, backed by a 46% 5-year profit CAGR.
  • A 10-year average ROE of 20% shows the business has earned returns above a typical cost of equity over a long period, not just in the recent upcycle.
Bear Case 8
  • The valuation is high. A P/E of 69.5 gives an earnings yield of about 1.4%, so the price assumes the recent high growth rates will continue.
  • The price-to-book ratio of 16.28 implies a book value of only about ₹1,634 crore against a ₹26,595 crore market cap, leaving little asset-based downside protection.
  • The stock's 1-year return of 141% is ahead of 104% TTM profit growth, so part of the gain came from the market paying a higher multiple rather than from earnings alone.
  • Promoter holding has fallen by 6.75 percentage points over the last 3 years, which may worry investors who watch insider alignment.
  • TTM profit growth of 104% compares with a 5-year CAGR of 46%. If growth returns to its longer-term trend, the 69.5x multiple could come under pressure.
  • Shareholders get almost no income. The dividend yield is 0.08%, an implied payout of about ₹21 crore on roughly ₹383 crore of TTM profit, so returns depend almost entirely on the share price.
  • ROE averaged only 18% over 3 and 5 years, which is modest next to a 16.28x price-to-book multiple. The 24% ROE from last year would need to hold to support the premium.
  • Key data is missing, including 10-year sales, profit and stock growth, the debt-to-equity figure and the 52-week price range. This makes it harder to judge performance across full business cycles.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

1d ago
Positives 2
  • HPAPI pilot plant commissioned Sep 4

    Acutaas opened a new pilot plant at Unit 1, Sachin, Surat on September 4, 2026, with OEB 4 containment for highly potent API intermediates. It supports new product trials and process scale-up for targeted therapies such as oncology, which are higher-value niches.

  • Patent count rises to 11 Sep 10

    Acutaas secured a process patent for preparing 2,4-dimethylthiophenol, bringing its total to 11 patents. This strengthens its IP portfolio and shows ongoing R&D output.

Neutral 3
  • 19th AGM approves FY26 accounts Sep 24

    At the 19th AGM on September 24, 2026, shareholders adopted the FY26 financials and declared a final dividend. They also passed resolutions on director reappointments and related party transactions.

  • EAOPL made direct subsidiary Sep 24

    The board approved acquiring 100% of step-down subsidiary Enchem Ami Organics Pvt Ltd for ₹1 lakh, making it a direct wholly owned subsidiary. This is an internal group restructuring with no material financial impact.

  • PL Capital conference on Sep 28 Sep 22

    Acutaas will take part in the PL Capital Mid & Small Cap Conference in Mumbai on September 28, 2026. The company confirmed it will not share any price-sensitive information.

TL;DR: Acutaas is building its R&D and specialty capabilities, with an OEB 4 HPAPI pilot plant for oncology-focused work and an 11th process patent. The other items are routine: AGM approvals, a dividend, a ₹1 lakh subsidiary restructuring and an investor conference. No clear headwinds appear in this news set, though the articles include no revenue, margin or order-book data to confirm momentum in operations. The direction looks steady to improving, and the next signal to watch is whether the HPAPI capacity turns into commercial contracts in the coming quarters.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
154
172
166
225
177
247
275
308
207
306
393
433
330
Expenses
120
148
140
182
147
198
206
224
156
211
243
249
217
Operating Profit
34
25
27
43
30
49
69
85
51
95
151
184
113
OPM %
22%
14%
16%
19%
17%
20%
25%
28%
25%
31%
38%
42%
34%
Other Income
1
-30
3
1
1
8
2
6
16
10
5
11
2
Interest
1
1
3
2
4
0
1
1
1
1
1
1
1
Depreciation
4
4
4
5
6
7
6
7
8
8
10
10
10
PBT
31
-10
24
37
20
50
63
83
58
96
145
184
104
Tax %
28%
71%
25%
31%
26%
25%
28%
24%
24%
25%
27%
27%
28%
Net Profit
22
-17
18
26
15
38
45
63
44
72
106
134
75
EPS in Rs
2.71
-2.55
2.27
3.41
1.71
4.56
5.49
7.63
5.41
8.82
13.19
16.09
9.07
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
160
188
239
240
341
520
617
717
1,007
1,339
1,462
Expenses
137
157
196
198
260
415
493
589
775
859
919
Operating Profit
23
31
42
42
80
105
123
128
232
480
543
OPM %
14%
16%
18%
17%
24%
20%
20%
18%
23%
36%
37%
Other Income
0
3
0
2
1
3
4
-25
17
42
27
Interest
3
3
5
6
6
6
2
6
6
3
4
Depreciation
1
2
3
4
4
10
12
16
27
36
38
PBT
19
28
35
35
72
91
112
82
216
483
529
Tax %
35%
35%
34%
21%
25%
21%
26%
41%
26%
26%
—
Net Profit
12
18
23
27
54
72
83
49
160
356
387
EPS in Rs
40.17
61.67
11.1
13.08
8.57
9.87
11.43
5.8
19.38
43.51
47.17
Div. Payout %
0%
0%
0%
0%
0%
15%
13%
26%
8%
6%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
2
2
10
10
32
36
36
37
41
41
Reserves
37
56
72
101
135
486
558
637
1,269
1,613
Borrowings
27
44
54
59
137
1
4
217
13
36
Other Liabilities
43
54
77
61
110
136
169
205
227
295
Total Liabilities
109
155
213
232
413
659
767
1,096
1,549
1,984
Fixed Assets
28
32
79
85
186
205
259
427
570
745
CWIP
11
30
2
12
0
3
30
125
130
332
Investments
1
3
2
2
1
2
2
0
0
0
Other Assets
68
91
131
133
225
450
477
543
848
907
Total Assets
109
155
213
232
413
659
767
1,096
1,549
1,984
Figures in ₹ Crores

Cash Flow

Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
29
8
15
27
28
-12
66
125
118
292
Investing
-19
-25
-21
-24
-101
-121
-33
-365
-224
-266
Financing
-7
15
6
0
72
140
-12
239
261
4
Net Cash Flow
3
-2
0
3
-1
8
20
-1
156
30
Free Cash Flow
10
-16
-7
6
-77
-46
-31
-155
-76
-36
CFO/OP
153
53
68
85
52
10
73
116
71
84
Figures in ₹ Crores

Ratios

Particulars Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
83
97
116
86
129
115
136
105
105
99
Inventory Days
76
89
95
148
123
150
131
139
119
149
Days Payable
148
154
168
146
172
158
157
119
103
99
Cash Conversion Cycle
11
31
43
88
80
107
111
125
121
149
Working Capital Days
46
64
28
34
51
141
139
80
123
116
ROCE %
—
38%
34%
27%
33%
24%
21%
16%
20%
32%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Acutaas Chemicals insights

69 extracted metrics + investor summaries across FY14–FY27.

Log in — free

Shareholding Pattern

Govt.0.01%Promot.32.66%Public21.72%Others4.44%DIIs19.56%FIIs21.61%As ofJun 2026

Documents

Frequently Asked Questions about Acutaas Chemicals

What does Acutaas Chemicals Ltd do?
Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals...
Where is Acutaas Chemicals Ltd (ACUTAAS) listed?
Acutaas Chemicals Ltd trades as ACUTAAS on the NSE and under code 543349 on the BSE.
Which sector does Acutaas Chemicals Ltd belong to?
Acutaas Chemicals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Acutaas Chemicals Ltd?
Acutaas Chemicals Ltd has a market capitalisation of ₹26,347 Cr, which places it in the Large Cap band.
What is the PE ratio of Acutaas Chemicals Ltd?
Acutaas Chemicals Ltd trades at a PE ratio of 67.77, on earnings per share of ₹15.13, against a book value of ₹201.97 per share.
What is the 52-week high and low of Acutaas Chemicals Ltd?
Over the last 52 weeks Acutaas Chemicals Ltd has traded between ₹1,302 and ₹3,740.
Does Acutaas Chemicals Ltd pay dividends?
Acutaas Chemicals Ltd has a dividend yield of 0.08%.
What is the Return on Equity (ROE) of Acutaas Chemicals Ltd?
Acutaas Chemicals Ltd reported a return on equity of 20.83%. Its debt-to-equity ratio is 0.02.

Company Information

Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals.[1]

Website amiorganics.com
CEO Mr. Nareshkumar Ramjibhai Patel
Employees 879
Listed 2021-09-14
Face Value ₹ 5
Issued Size 8,18,71,122

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ACUTAAS.md for Acutaas Chemicals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List